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Introduction
The prevalence of chronic kidney disease (CKD) has 
markedly increased over the past 10 years, and CKD has 
become a public health problem worldwide [1]. Because 
CKD is progressive and causes declining kidney function, 
it is critical to establish a confirmative risk stratification 
strategy and correct reversible risk factors. CKD can jeop-
ardize patient health, work performance, and well-being, 
particularly when kidney function is seriously decreased 
[2].
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Background: Cardiovascular disease and chronic kidney disease share several common risk factors. The Framingham 
risk score is hypothesized to predict chronic kidney disease development. We determined if the Framingham risk 
scoring system can correctly predict incident chronic kidney disease in the general population.
Methods: This study included 9,080 subjects who participated in the Korean Genome and Epidemiology Study 
between 2001 and 2014 and had normal renal function. The subjects were classified into low- (< 10%), intermediate- 
(10-20%), and high- (> 20%) risk groups based on baseline Framingham risk scores. The primary endpoint was de 
novo chronic kidney disease development (estimated glomerular filtration rate [eGFR], < 60 mL/min/1.73 m2).
Results: During a mean follow-up duration of 8.9 ± 4.3 years, 312 (5.3%), 217 (10.8%), and 205 (16.9%) 
subjects developed chronic kidney disease in the low, intermediate, and high risk groups, respectively (P < 0.001). 
Multivariable analysis after adjustment for confounding factors showed the hazard ratios for the high- and 
intermediate risk groups were 2.674 (95% confidence interval [CI], 2.197-3.255) and 1.734 (95% CI, 1.447-2.078), 
respectively. This association was consistently observed irrespective of proteinuria, age, sex, obesity, or hypertension. 
The predictive power of this scoring system was lower than that of renal parameters, such as eGFR and proteinuria, 
but increased when both were included in the prediction model.
Conclusion: The Framingham risk score predicted incident chronic kidney disease and enhanced risk stratification in 
conjunction with traditional renal parameters in the general population with normal renal function.
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Many well-known traditional risk factors predispose 
patients to CKD, including diabetes mellitus and hyper-
tension. Many researchers have attempted to find novel 
biomarkers and predictive values for CKD [3]. However, 
these biomarkers are generally assessed only for research 
purposes and are not easily adopted in clinical practice. 
Currently, there is no widely accepted instrument that 
comprehensively integrates risk factors associated with 
incident CKD development. The ideal model should ac-
curately predict future events, be easily implemented, 
and universally generalize to diverse populations.
The Framingham Heart Study started in 1948 and in-
cluded 5,209 adults from Framingham, Massachusetts, 
USA [4]. This long-term cohort study has greatly contrib-
uted to the identification of cardiovascular disease (CVD) 
risk factors and facilitated the development of useful 
clinical tools to predict absolute CVD risk [5]. The Fram-
ingham prediction algorithms have been widely adopted 
to assess absolute risk and guide the intensity of risk fac-
tor interventions. The Framingham risk score has been 
validated by many studies and is the most commonly 
used algorithm in clinical practice. The original score 
was intended for use in non-diabetic patients aged 30 to 
74 years with no coronary heart disease or intermittent 
claudication history. In 2008, it was revised and became 
the Framingham general CVD risk score [6].
Interestingly, CKD and CVD share common traditional 
risk factors, such as smoking, obesity, hypertension, 
diabetes mellitus, and dyslipidemia [7-9]. Furthermore, 
major adverse cardiac and cerebrovascular events occur 
more frequently in patients with estimated glomerular 
filtration rate (eGFR) < 60 mL/min/1.73 m2 than in those 
with normal renal function [10]. Conversely, uremic 
toxin, which accumulates in CKD, is strongly associated 
with adverse cardiovascular events and reducing uremic 
toxin may confer renal and cardiovascular protection [11]. 
Because the Framingham risk score is well validated for 
cardiovascular risk stratification, we aimed to determine 
whether it can perform equally well and correctly predict 
incident CKD in the general population.
Methods
Study population
We used data from the Korean Genome and Epidemiol-
ogy Study, which is a population-based prospective co-
hort study performed to assess the prevalence, incidence, 
and risk factors for chronic degenerative disorders, such 
as hypertension, diabetes mellitus, and CVD. Two repre-
sentative communities comprised this cohort: Anseong 
(rural) and Ansan cohorts (urban). Each cohort consisted 
of Korean males and females aged 40 to 69 years with a 
homogeneous ethnic background.
The baseline survey was performed from 2001 to 2002 
in a cohort of 10,030 adults who were repeatedly exam-
ined at 2-year intervals. Of this sample, 950 individuals 
were excluded for the following reasons: baseline eGFR 
of < 60 mL/min/1.73 m2 (n = 223); underlying kidney dis-
ease (n = 268); missing Framingham risk score (n = 125); 
missing past history (n = 4); missing alcohol consump-
tion data (n = 29); missing body mass index (BMI) data 
(n = 3); and missing laboratory test data (n = 298). A total 
of 9,080 participants were finally included in the current 
study sample (Fig. 1).
This study was conducted according to the Declaration 
of Helsinki guidelines. All subjects were fully informed of 
the study content and provided written informed consent 
for data use. The study was approved by the Institutional 
Review Board of Yonsei University Health System Clinical 
Trial Center (IRB no. 4-2016-0100).
Clinical and laboratory measurements
All participants underwent comprehensive health 
examinations and interviews according to the site visit 
schedule. The health examination included an anthropo-
metric index evaluation and biological specimen collec-
tion. Participants completed interviewer-administered 
questionnaires including questions on age, current 
smoking, alcohol intake (at least once per month), mari-
tal status, and educational level. BMI was calculated as 
follows: weight (kg)/height (m2). Waist circumference 
was measured along a horizontal plane midway between 
the inferior margin of the ribs and superior border of 
the iliac crest. Participants also completed interviewer-
administered questionnaires regarding their medical his-
tories including medication use, family disease history, 
and lifestyle factors, such as smoking status and alcohol 
intake. Blood pressure was measured using mercury 
sphygmomanometers (Baumanometer-Standby; W. A. 
Baum Co., Inc., Copiague, NY, USA). All subjects were in-
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structed to relax in the sitting position for at least 10 min 
before blood pressure measurement. The mean of two 
blood pressure readings was used for analyses.
After at least 8 hours of fasting, blood, and urine sam-
ples were collected and delivered to a central laboratory 
(Seoul Clinical Laboratories, Seoul, Korea) within 24 
hours of sampling. Plasma was separated by centrifuga-
tion (2,000 revolution per minute, 20 minutes at 4°C), 
and biochemical measurements were conducted imme-
diately. The plasma concentrations of glucose, total cho-
lesterol, triglycerides, and high-density lipoprotein-cho-
lesterol (HDL-C) were measured enzymatically using a 
747 Chemistry Analyzer (Hitachi, Tokyo, Japan). The low-
density lipoprotein-cholesterol (LDL-C) concentration 
was calculated using Friedewald’s equation [12]. The se-
rum creatinine concentration was measured using Jaffe’s 
method with a Hitachi Automatic Analyzer 7600 (Hitachi). 
Urinalysis was performed using fresh urine samples and 
measured semiquantitatively using the urine dipstick test 
(URISCAN Pro II; YD Diagnostics Corp., Yongin, Korea) 
with the findings reported using six grades: absent, trace, 
1+, 2+, 3+, and 4+. Proteinuria was defined as presence 
of protein ≥ 1+. Because creatinine was not measured 
using an isotope dilution mass spectrometry-traceable 
method, we adjusted creatinine levels using a conversion 
equation [13]. The eGFR was then calculated using the 
CKD-Epidemiology Collaboration equation: eGFR (mL/
min/1.73 m2) = 141 × min (serum creatinine [sCr]/κ, 1)α × 
max (sCr/κ, 1)-1.209 × 0.993age (yr) × 1.018 (if women) × 1.159 
(if black), where κ is 0.7 for women and 0.9 for men; α is 
-0.329 for women and -0.411 for men; min indicates the 
minimum of sCr/κ or 1; and max indicates the maximum 
of sCr/κ or 1. This equation can more precisely estimate 
kidney function in people with eGFR ≥ 60 mL/min/1.73 
m2 [14].
The Framingham risk score
Framingham general CVD risk scores were calculated 
for the total study population based on the following 
characteristics: age, smoking history (current, past, or 
never), diabetes mellitus (absence or presence), systolic 
blood pressure (mmHg), HDL-C concentration (mg/dL), 
and total cholesterol concentration (mg/dL). The Fram-
ingham risk score ranges from -3 to 21+ and indicates 
10-year risk of developing CVD. The subjects were classi-
fied into three risk groups according to their scores: low 
(< 13 in women, < 11 in men; risk, < 10%), intermediate 
(13-17 in women, 11-14 in men; risk, 10-20%), and high 
(> 17 in women, > 14 in men; risk, > 20%) [6].
Study endpoint
The primary outcome was de novo CKD development, 
defined as the development of CKD stage 3, which is 
eGFR of < 60 mL/min/1.73 m2 for at least two consecu-
tive measurements during follow-up. The first of these 
measurements was designated to be the study endpoint. 
Secondary outcomes included decline in an eGFR ≥ 40 
mL/min/1.73 m2 from the baseline value during follow-
10,030 subjects were screened
eGFR < 60 mL/min/1.73 m (n = 223)
Past chronic kidney disease history (n = 268)
Missing Framingham risk score (n = 125)
Missing past history (n = 4)
Missing drinking data (n = 29)
Missing BMI (n = 3)
Missing labolatory teat
(CRP, fasting glucose, urine protein) (n = 298)
2
9,080 subjects were eligible
Framingham risk group
Low risk (< 10%)
n = 5,858 (64.5%)
Intermediate risk (10 20%)
n = 2,012 (22.2%)
High risk (> 20%)
n = 1,210 (13.3%)
Figure 1. Flow diagram of study co-
hort.
BMI, body mass index; CRP, C-reactive 
protein; eGFR, estimated glomerular 
filtration rate; HDL, high density lipopro-
tein. 
Kidney Res Clin Pract   Vol. 38, No. 1, March 2019
52 www.krcp-ksn.org
up, annual decline in eGFR, and development of protein-
uria ≥ 1+. Proteinuria was analyzed only in subjects with 
proteinuria < 1+.
Statistical analysis
Statistical analyses were performed using IBM SPSS 
for Windows version 23.0 (IBM Corp., Armonk, NY, 
USA). Continuous variables were presented as means ± 
standard deviations or medians (interquartile ranges) 
and categorical variables as frequencies and percent-
ages. Patient characteristics were compared using one-
way analysis of variance for continuous variables and 
chi-square tests for categorical variables. The Kruskal-
Wallis test was used for data with skewed distributions. 
The cumulative incidence of CKD stage 3 in the three risk 
groups was assessed using Kaplan-Meier plots. Survival 
time was defined as the time between enrollment and 
first renal outcome onset. There were 887 (9.8%) patients 
who were lost to follow-up, and these were censored at 
the last examination date. To detect independent asso-
ciations between Framingham risk score and incident 
stage 3, we constructed stepwise multivariable Cox pro-
portional hazard models. Model 1 represents crude risk 
without adjustment. Model 2 was adjusted for residence 
(Ansan or Anseong), educational level, income, coronary 
artery disease history, and alcohol intake (non-drinker, 
ex-drinker, or current drinker). We constructed model 3 
after adjustments for renal parameters, including eGFR 
and proteinuria. Finally, we constructed model 4 after in-
cluding fasting glucose, albumin, triglyceride, C-reactive 
protein (CRP), and LDL-C concentrations. Results were 
expressed as hazard ratios (HRs) with 95% confidence 
intervals (CIs). The rate of renal function decline per year 
was assessed using the slope of eGFR obtained from a 
generalized linear mixed model. We used receiver-op-
erating characteristic (ROC) curve analysis and C-index 
estimation to compare the accuracies of the Framingham 
risk score and of other individual traditional risk factors. 
Finally, to provide an unbiased evaluation of the cohort 
dataset, we conducted internal validation for the final 
model using a 10-fold cross-validation technique. The 
original data set was randomly partitioned into 10 equal-
ly-sized subsamples (n = 908). Of the 10 subsamples, a 
single sample acted as the test data set for the prediction 
model, and the remaining 9 subsamples were treated as 
training data sets. The cross-validation technique was 
then repeated 10 times, with each of the 10 subsamples 
used exactly once as the validation data. The average of 
the 10 iterations was calculated to assess the reliability 
for the model. Then, we performed ROC and C-statistics 
analyses. P values less than 0.05 were considered statisti-
cally significant.
Results
Baseline patient characteristics
The baseline patient characteristics according to the 
Framingham risk groups are shown in Table 1. The mean 
age was 51.8 ± 8.7 years, and 4,412 (48.6%) subjects were 
male. Of the 9,080 subjects, there were 5,850 (64.4%), 
2,012 (22.2%), and 1,210 (13.3%) subjects in the low (< 
10%), intermediate (10-20%), and high (> 20%) risk 
groups, respectively. The high- and intermediate risk 
group subjects were older and had lower eGFR than the 
low risk group subjects. Not surprisingly, there were more 
subjects with hypertension and smokers in the high risk 
group; they also had higher total cholesterol, triglyceride, 
LDL-C, and CRP concentrations than the low risk group 
subjects. The proportion of subjects with lower income 
and educational levels was also higher in the high risk 
group.
Incident CKD risk according to Framingham risk score 
groups
A total of 734 (8.1%) renal events occurred during a 
mean follow-up duration of 8.9 ± 4.3 years. There were 
312 (5.3%), 217 (10.8%), and 205 (16.9%) subjects who 
developed CKD stage 3 in the low, intermediate, and 
high risk groups, respectively (P < 0.001) (Table 2). The 
Kaplan-Meier curve for incident CKD stage 3 accord-
ing to Framingham risk score group is shown in Fig. 2. 
The number of cumulative renal events was significantly 
higher in the high risk group than in the low risk group. 
The intermediate risk group also had a higher number of 
cumulative renal events than the low risk group. As ex-
pected, more cardiovascular events occurred in the high 
risk group (Table 2).
Next, we constructed stepwise multivariable Cox mod-
els to confirm this association. The association was simi-
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lar in multivariable analysis after adjustment for demo-
graphic factors, including residence (Ansan or Anseong), 
socioeconomic status, alcohol status, and coronary 
artery disease history. Further adjustments for eGFR and 
proteinuria yielded the same results. In model 4, with 
further adjustments for fasting glucose, albumin, tri-
glyceride, CRP, and LDL-C concentrations, the high risk 
group had a 2.7-fold increased risk of incident CKD stage 
3 risk compared with the low risk group (HR, 2.674; 95% 
CI, 2.197-3.255; P < 0.001). In this fully adjusted model, 
Table 1. Baseline characteristics of patients classified by Framingham risk score
Variable
Total 
(n = 9,080)
Low risk 
(n =5,858)
Intermediate risk 
(n = 2,012)
High risk 
(n = 1,210)
P value
Demographic data
    Age (yr) 51.8 ± 8.7 48.8 ± 7.6 55.2 ± 8.3 60.5 ± 6.5 < 0.001
    Sex, male 4,412 (48.6) 1,961 (33.5) 1,440 (71.6) 1,011 (83.6) < 0.001
    Monthly wage, < $1,090 3,062 (33.7) 1,607 (27.4) 827 (41.1) 628 (51.9) < 0.001
    Married 8,958 (98.7) 5,776 (98.6) 1,982 (98.5) 1,200 (99.2) 0.233
    Education ≥ 9 yr 1,270 (14.0) 836 (14.3) 303 (15.1) 131 (10.8) 0.002
    SBP (mmHg) 121.1 ± 18.2 114.8 ± 14.3 128.9 ± 18.4 138.2 ± 18.8 < 0.001
    DBP (mmHg) 80.2 ± 11.4 77.0 ± 10.2 85.0 ± 11.3 87.7 ± 10.7 < 0.001
    eGFR (mL/min/1.73 m2) 92.9 ± 13.2 94.9 ± 13.0 90.1 ± 12.7 87.6 ± 12.2 0.009
    Body mass index (kg/m2) 24.5 ± 3.1 24.5 ± 3.1 24.8 ± 3.2 24.4 ± 3.2 0.099
    Smoking status < 0.001
        Never 5,268 (58.0) 4,249 (72.5) 767 (38.1) 252 (20.8)
        Former 1,426 (15.7) 839 (14.3) 393 (19.5) 194 (16.0)
        Current 2,386 (26.3) 770 (13.1) 852 (42.4) 764 (63.1)
    Alcohol status < 0.001
        Never 4,121 (45.4) 3,066 (52.3) 716 (35.6) 339 (28.0)
        Former 578 (6.4) 262 (4.5) 180 (8.9) 136 (11.2)
       Current 4,381 (48.2) 2,530 (43.2) 1,116 (55.5) 735 (60.7)
Comorbidities 
    Hypertension 1,253 (13.8) 375 (6.4) 444 (22.1) 434 (35.9) < 0.001
    Diabetes mellitus 369 (4.1) 85 (1.5) 119 (5.9) 165 (13.6) < 0.001
    Coronary artery disease 64 (0.7) 24 (0.4) 25 (1.2) 15 (1.2) < 0.001
    Myocardial infarction 70 (0.8) 31 (0.5) 19 (0.9) 20 (1.7) < 0.001
    Cerebrovascular accident 92 (1.0) 24 (0.4) 38 (1.9) 30 (2.5) < 0.001
Laboratory parameters
    Fasting glucose (mg/dL) 92.3 ± 22.6 89.2 ± 15.5 95.3 ± 26.0 102.7 ± 37.1 < 0.001
    BUN (mg/dL) 14.2 ± 3.6 14.0 ± 3.5 14.7 ± 3.6 14.8 ± 3.8 < 0.001
    Creatinine (mg/dL) 0.83 ± 0.17 0.81 ± 0.16 0.88 ± 0.17 0.89 ± 0.16 < 0.001
    Hemoglobin (g/dL) 13.6 ± 1.6 13.2 ± 1.6 14.2 ± 1.4 14.4 ± 1.3 < 0.001
    Total cholesterol (mg/dL) 191.2 ± 35.5 187.5 ± 33.4 198.0 ± 37.1 197.5 ± 40.1 < 0.001
    HDL-C (mg/dL) 49.7 ± 11.9 51.2 ± 11.9 47.4 ± 11.6 46.3 ± 10.9 < 0.001
    Triglyceride (mg/dL) 151.4 ± 108.4 133.1 ± 90.4 177.5 ± 124.9 196.2 ± 133.9 < 0.001
    cLDL-C (mg/dL) 114.6 ± 32.8 113.1 ± 30.6 118.2 ± 35.1 115.6 ± 38.1 < 0.001
    CRP (mg/dL) 0.14 (0.07-0.36) 0.13 (0.06-0.22) 0.17 (0.08-0.29) 0.17 (0.09-0.33) < 0.001
    Albumin (g/dL) 4.2 ± 0.3 4.2 ± 0.3 4.3 ± 0.3 4.2 ± 0.3 0.002
    Urine protein ≥ 1+ 190 (2.1) 97 (1.7) 46 (2.3) 47 (3.9) < 0.001
Data are presented as mean ± standard deviation or number (%), if variable showed skewed deviation, presented as median ± interquartile range.
BUN, blood urea nitrogen; cLDL-C, calculated low density lipoprotein-cholesterol; CRP, C-reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular 
filtration rate; HDL-C, high density lipoprotein-cholesterol; SBP, systolic blood pressure.
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the intermediate risk group had a 1.7-fold increased CKD 
stage 3 risk (HR, 1.734; 95% CI, 1.447-2.078; P < 0.001) 
(Table 3). The increased risk of CKD stage 3 development 
associated with high Framingham risk score was also 
found in the secondary analysis, in which decline in an 
eGFR ≥ 40 mL/min/1.73 m2 from the baseline value was 
the secondary outcome (Supplementary Table 1). When 
we compared renal function decline among Framingham 
risk score groups, eGFR declined faster in the highest 
score group than in the lowest and middle score groups 
(Supplementary Table 2).
Relationship between Framingham risk scores and new-
onset proteinuria
We further analyzed if the Framingham risk score pre-
dicted new development of proteinuria during follow-
up in subjects without baseline proteinuria. The results 
showed that higher Framingham risk scores were as-
sociated with increased risk of proteinuria development 
(Supplementary Table 3).
Predictive value of the Framingham risk score and other 
risk factors
We performed ROC curve analyses to compare the 
value of the Framingham risk score for predicting CKD 
stage 3 incidence to that of other traditional risk factors. 
The area under the curve (AUC) for the Framingham risk 
score-added model (model 2) was 0.699 (95% CI, 0.679–
0.719) as compared to 0.631 (95% CI, 0.610-0.652; P < 
0.001) for the baseline model (model 1) (Fig. 3). However, 
the AUC for the renal parameter-added model (model 
3) was significantly higher than that for the Framingham 
risk score-added model. Inclusion of the Framingham 
risk score with renal parameters yielded the highest AUC 
(0.813; 95% CI, 0.798-0.827).
We then compared the predictive power of the Fram-
ingham risk score with that of Harrell’s C index for three 
multivariable Cox regression models (Table 4). Consider-
ing the ROC analysis results, the predictive power of the 
Framingham risk score was lower than that of the renal 
parameters. However, adding the Framingham risk score 
to the renal parameters significantly improved predic-
tive ability compared to a model using renal parameters 
alone (model 4; C-statistic, 0.839; 95% CI, 0.825-0.853; 
P < 0.001). These findings suggest that the predictive 
value of the risk stratification model for future CKD stage 
3 can increase when the Framingham risk score is con-
sidered in addition to kidney function and proteinuria. 
Table 2. Renal and cardiovascular outcomes classified by Framingham risk score
Total
Framingham risk score groups
Low risk Intermediate risk High risk
No. of participants 9,080 5,858 2,012 1,210
Person-year 80,521.1 53,193.2 17,415.6 9,912.3
eGFR < 60 mL/min/1.73 m2
    Events 734 312 217 205
    Events/1,000 person-year 9.3 5.9 12.8 21.8
Cardiovascular events
    Events 246 111 75 60
    Events/1,000 person-year 3.1 2.1 4.4 6.3
Data are presented as number person-year or incidence rate per 1,000 person-year.
eGFR, estimated glomerular filtration rate.
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Figure 2. Kaplan-Meier curve for incident chronic kidney dis-
ease development according to Framingham risk score.
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To finalize the model, internal validity was assessed us-
ing a 10-fold cross-validation procedure. This technique 
provides an estimate of the performance of the model 
when applied to test subsets. Following 10-fold cross-
validation, the mean C-statistic across folds was 0.837 
(95% CI, 0.797-0.867), and the mean AUC across folds 
was 0.810 (95% CI, 0.796-0.825) (Supplementary Table 4 
and Supplementary Fig. 1).
To clarify the robust association between the Framing-
ham risk score and CKD stage 3 development, subgroup 
analysis was performed in subgroups stratified by pro-
teinuria (≥ 1+ or no), age (< 60 or ≥ 60 years), sex (male or 
female), hypertension (yes or no), and BMI (< 25 or ≥ 25 
kg/m2). There were no significant interactions between 
the Framingham risk score and subgroup parameters 
(Fig. 4). Thus, increased risk of incident CKD stage 3 in 
the high risk group was consistently observed irrespec-
tive of proteinuria, age, sex, obesity, or hypertension.
Supplementary materials are presented online (avail-
able at https://doi.org/10.23876/j.krcp.18.0118).
Discussion
In this study, the Framingham risk score effectively pre-
dicted incident CKD stage 3 in the general population. Its 
predictive power was lower than that of renal parameters, 
such as eGFR and proteinuria, but increased when both 
were included in the prediction model. Thus, the Fram-
ingham risk score considered together with traditional 
renal risk factors can improve risk stratification for CKD 
stage 3 development in healthy individuals without kid-
ney disease.
CVD and CKD are major public health problems world-
wide [15-18]. Lifelong CKD risk is substantial and CKD 
symptoms or signs are almost always absent until 90% 
of kidney function is lost [19]. Because established CKD 
is irreversible, there is growing emphasis on the impor-
tance of early detection and intervention for high risk in-
dividuals. There are many common risk factors between 
CVD and CKD. Given the paucity of risk assessment tools 
for CKD development, high risk individual identification 
using well-known validated scoring systems would be 
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Figure 3. Receiver operating characteristics curve for 4 models 
predicting incident chronic kidney disease. Model 1, sex, body 
mass index, education level, income, fasting glucose, and serum al-
bumin; Model 2, model 1 + Framingham risk score; Model 3, model 
1 + eGFR + proteinuria; Model 4, model 1 + eGFR + proteinuria + 
Framingham risk score.
AUC, area under the curve; CI, confidence interval; eGFR, estimated 
glomerular filtration rate; NA, not applicable.
Table 3. Multivariate Cox regression analysis of incidental chronic kidney disease in patients according to Framingham risk score 
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Low risk 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Intermediate risk 2.252 
(1.893-2.678)
< 0.001 2.454 
(2.053-2.933)
< 0.001 1.837 
(1.538-2.193)
< 0.001 1.734 
(1.447-2.078)
< 0.001
High risk 4.239 
(3.553-5.057)
< 0.001 4.704 
(3.899-5.674)
< 0.001 3.157 
(2.621-3.803)
< 0.001 2.674 
(2.197-3.255)
< 0.001
Model 1, crude hazard ratio (HR) without adjustment; Model 2, adjusted for residence (Ansan or Anseong), education status, income, history of coronary artery 
disease, alcohol intake (non-drinker, ex-drinker, or current drinker); Model 3, model 2 + eGFR and proteinuria; Model 4, model 3 + fasting glucose, albumin, 
triglyceride, C-reactive protein, and calculated low density lipoprotein.
CI, confidence interval; eGFR, estimated glomerular filtration rate. 
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helpful.
To date, only three studies have proposed risk predic-
tion models for incident CKD. In a combined cohort 
study of 14,155 middle-aged adults from the Atheroscle-
rosis Risk in Communities (ARIC) Study and Cardio-
vascular Health Study, Kshirsagar et al [20] developed 
a simple algorithm including eight variables: age, sex, 
anemia, hypertension, diabetes mellitus, peripheral vas-
cular disease, and histories of CVD and heart failure. The 
incident CKD risk increased with the risk score, indicat-
ing that this algorithm is helpful for CKD prevention in 
healthy individuals without kidney diseases [20]. Chien 
et al [21] also constructed a risk prediction system using a 
Chinese cohort, which included age, BMI, diastolic blood 
pressure, diabetes mellitus, stroke, proteinuria, and uric 
acid, postprandial glucose, and hemoglobin A1c con-
centrations. Their risk model was also useful for predict-
ing CKD [21]. Finally, O’Seaghdha et al [22] developed 
a prediction model using the Framingham cohort that 
incorporated five variables: age, diabetes mellitus, hyper-
tension, eGFR, and albuminuria. This model was further 
validated in the ARIC cohort. 
Our findings are consistent with those of all previous 
studies [20-22]. This was not surprising, because the 
variables used to construct models overlapped among 
studies. Age, hypertension, and diabetes mellitus are rep-
Table 4. C-statistics for prediction of incident chronic kidney disease using multivariate Cox regression models
Model C-statistics (95% CI)
P for difference of C-statistics compared with models
Model 1 Model 2 Model 3 Model 4
Model 1 0.652 (0.631-0.674) NA - - -
Model 2 0.729 (0.709-0.749) < 0.001 NA - -
Model 3 0.819 (0.804-0.833) < 0.001 < 0.001 NA -
Model 4 0.839 (0.825-0.853) < 0.001 < 0.001 < 0.001 NA
Model 1, sex, body mass index, education level, income, fasting glucose, and serum albumin; Model 2, model 1 + the Framingham risk score; Model 3, model 1 + 
eGFR and proteinuria; Model 4; model 1 + eGFR, proteinuria, and the Framingham risk score. 
CI, confidence interval; eGFR, estimated glomerular filtration rate; NA, not applicable.
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Figure 4. Forest plot for subgroup analysis.
BMI, body mass index; CI, confidence interval; HR, hazard ratio; HTN, hypertension; N, number.
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resentative risk factors for CKD, and were incorporated 
in all studies including the present study. However, there 
are discrepancies in the predictive power of the models. 
The prediction model developed by Kshirsagar et al [20] 
had moderate discriminatory power (AUC, 0.70). Con-
versely, the models in two subsequent studies [21,22] had 
higher AUCs (0.765) or C-statistics (0.813) than did the 
model proposed by Kshirsagar et al [20]. This difference is 
presumably because Kshirsagar et al [20] did not include 
renal parameters, whereas the other studies incorporated 
proteinuria or eGFR. Proteinuria and initial kidney func-
tion were the strongest CKD predictors in the present 
study, although the subjects had a baseline eGFR of ≥ 60 
mL/min/1.73 m2. This relationship was clearly reflected 
in our findings. The Framingham risk score added to the 
clinical model was 0.699, which was similar to that in the 
study by Kshirsagar et al [20]. When we included both the 
Framingham risk score and renal parameters, the AUC 
and C-statistics for the model were the highest among all 
models. These results are numerically similar to those for 
the Chinese and Framingham cohorts [21,22].
Based on our findings, the present study has a number 
of clinical implications. First, the Framingham risk score 
itself can help stratify healthy middle-aged individuals 
at high risk for incident CKD. However, the predictive 
value of this scoring system is not greater than that of 
traditional renal parameters. This does not mean that 
its use in clinical practice is limited. The Framingham 
scoring system can be implemented in conjunction 
with proteinuria and eGFR for further risk stratification 
for future CKD. However, our findings also suggest that 
measurements of creatinine and proteinuria should be 
included in medical check-ups because these two pa-
rameters are the strongest predictors of CKD develop-
ment. Second, this strategy can determine the estimated 
risks of CVD and CKD simultaneously, and thus may help 
guide clinical decision-making and counseling to obtain 
better outcomes. For example, early primary prevention 
strategies can be targeted to individuals at high CVD and 
CKD risks, including timely medical treatment initiation, 
adherence to lifestyle modification encouragement, sus-
tained awareness of exposure to nephrotoxic drugs, and 
early cardiologist or nephrologist referral for screening 
programs.
There are several limitations to the present study that 
should be discussed. First, we included only Korean indi-
viduals aged 40 to 69 years; thus, our findings may not be 
generalized to other ethnic or more elderly populations. 
Notably, previous studies that developed and tested risk 
score models for CKD in Chinese, European, and African-
American populations have shown similar results [20-22]. 
All of these studies incorporated similar variables to create 
prediction models. Given the high AUC and C-statistics of 
the models in all studies, the use of this strategy appears 
valid in diverse populations. Second, we did not mea-
sure other novel biomarkers and used only conventional 
factors. It is uncertain whether novel biomarkers can 
improve risk stratification relative to conventional fac-
tors. Previous studies suggest that improvements in CVD 
predictions using some biomarkers were marginal [23,24]. 
Therefore, measurements of these biomarkers may not 
be cost-effective. In contrast, our strategy is inexpensive, 
well-validated, easily applicable, and can assess both 
CKD and CVD risks. The AUC in our model including 
the Framingham risk score, proteinuria, and eGFR was 
0.813, and adding additional biomarkers to this model is 
unlikely to significantly increase the AUC. Third, we used 
dipstick tests of proteinuria but did not directly measure 
albuminuria. Albuminuria is a well-known risk factor for 
end-stage kidney disease and also predicts future CVD. 
Nevertheless, dipstick proteinuria was associated with 
increased incident CKD stage 3 risk (HR, 2.706; 95% CI, 
2.224-3.292; P < 0.001). The Framingham risk score was 
predictive only in people without proteinuria, but not in 
those with proteinuria. This finding was unexpected, as 
the Framingham risk score and proteinuria are both good 
markers of vascular injury. However, many people at risk 
for CVD can have CKD even without proteinuria. In ad-
dition, our cohort included only 190 (2.1%) subjects with 
proteinuria, which may have resulted in lack of statistical 
power although there was a trend toward increased risk 
for CKD stage 3. Further analyses with a more adequate 
sample size could answer this issue in the future. Ad-
ditionally, we did not assess hyperglycemia severity or 
blood pressure in this study. Although there are debates 
regarding optimal glycemic and blood pressure control, 
these are both very important factors in preventing CVD 
and CKD. Further studies to develop more comprehen-
sive models encompassing these factors are warranted 
[25,26].
In conclusion, the Framingham risk score effectively 
predicted incident CKD stage 3 development in the gen-
Kidney Res Clin Pract   Vol. 38, No. 1, March 2019
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eral population with normal renal function. The predic-
tive value for future CKD stage 3 development was fur-
ther enhanced when this scoring system was considered 
in concert with proteinuria and eGFR. The Framingham 
risk score, together with traditional renal risk factors, 
can easily be used in the primary care setting to stratify 
healthy individuals at high risk for CKD stage 3.
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Supplementary Table 1. eGFR decline ≥ 40 mL/min/1.73 m2 from baseline outcomes among groups classified by Framingham 
risk score with multivariate Cox regression analysis
Total
Framingham risk score groups
Low risk Intermediate risk High risk
≥ 40 eGFR decline
    Events 679 450 133 96
    Events/1,000 person-year 9.9 8.6 7.7 9.9
Model 1 HR (95% CI) 1 [reference] 0.917 (0.756-1.113) 1.280 (1.026-1.595)
P 0.379 0.028
Model 2 HR (95% CI) 1 [reference] 0.958 (0.786-1.168) 1.313 (1.044-1.651)
P 0.674 0.020
Model 3 HR (95% CI) 1 [reference] 1.356 (1.106-1.662) 2.182 (1.717-2.772)
P 0.003 < 0.001
Model 4 HR (95% CI) 1 [reference] 1.222 (0.989-1.509) 1.727 (1.341-2.224)
P 0.063 < 0.001
Data are presented as number person-year or incidence rate per 1,000 person-year.
Model 1, crude hazard ratio (HR) without adjustment; Model 2, adjusted for residence (Ansan or Anseong), education status, income, history of coronary artery 
disease, alcohol intake (non-drinker, ex-drinker, or current drinker); Model 3, model 2 + eGFR and proteinuria; Model 4, model 3 + fasting glucose, albumin, 
triglyceride, C-reactive protein, and calculated low density lipoprotein.
CI, confidence interval; eGFR, estimated glomerular filtration rate.
Supplementary Table 2. Linear mixed model of annual eGFR decline according to Framingham risk group
Framingham risk score groups
Slope of
eGFR decline (95% CI)
P for-difference between groups
Low risk Intermediate risk High risk
Low risk -0.545 (-0.573 to -0.517) -
Intermediate risk -0.638 (-0.690 to -0.585) 0.002 -
High risk -0.861 (-0.940 to -0.781) < 0.001 < 0.001 -
Estimated glomerular filtration rate (eGFR) decline: biannual eGFR decline rate (mL/min/1.73 m2/year).
Su
pp
le
m
en
ta
ry
 T
ab
le
 3
. M
ul
tiv
ar
ia
te
 C
ox
 re
gr
es
si
on
 a
na
ly
si
s 
fo
r t
he
 d
ev
el
op
m
en
t o
f i
nc
id
en
t p
ro
te
in
ur
ia
 (≥
 1
+)
 a
cc
or
di
ng
 to
 F
ra
m
in
gh
am
 ri
sk
 s
co
re
 g
ro
up
s
M
od
el
 1
M
od
el
 2
M
od
el
 3
M
od
el
 4
H
R 
(9
5%
 C
I)
P
H
R 
(9
5%
 C
I)
P
H
R 
(9
5%
 C
I)
P
H
R 
(9
5%
 C
I)
P
Lo
w 
ris
k
1 
[re
fe
re
nc
e]
1 
[re
fe
re
nc
e]
1 
[re
fe
re
nc
e]
1 
[re
fe
re
nc
e]
In
te
rm
ed
ia
te
 ri
sk
3.
73
0 
(2
.4
51
-
5.
67
4)
3.
22
5 
(2
.0
99
-
4.
95
6)
3.
14
8 
(2
.0
40
-
4.
85
7)
< 
0.
00
1
3.
02
0 
(1
.9
35
-
4.
71
4)
< 
0.
00
1
Hi
gh
 ri
sk
5.
59
8 
(3
.6
00
-
8.
70
4)
4.
35
9 
(2
.7
41
-
6.
30
0)
4.
20
0 
(2
.6
18
-
6.
73
9)
< 
0.
00
1
3.
34
6 
(2
.0
28
-
5.
52
1)
< 
0.
00
1
M
od
el
 1
, c
ru
de
 h
az
ar
d 
ra
tio
 (H
R)
 w
ith
ou
t a
dj
us
tm
en
t; 
M
od
el
 2
, a
dj
us
te
d 
fo
r r
es
id
en
ce
 (A
ns
an
 o
r A
ns
eo
ng
), 
ed
uc
at
io
n 
st
at
us
, i
nc
om
e,
 h
is
to
ry
 o
f c
or
on
ar
y 
ar
te
ry
 d
is
ea
se
, a
lc
oh
ol
 in
ta
ke
 (n
on
-d
rin
ke
r, 
ex
-d
rin
ke
r, 
or
 
cu
rre
nt
 d
rin
ke
r);
 M
od
el
 3
, m
od
el
 2
 +
 e
GF
R 
an
d 
pr
ot
ei
nu
ria
 ; M
od
el
 4
, m
od
el
 3
 +
 fa
st
in
g 
gl
uc
os
e,
 a
lb
um
in
, t
rig
lyc
er
id
e,
 C
-re
ac
tiv
e 
pr
ot
ei
n,
 a
nd
 c
al
cu
la
te
d 
lo
w
 d
en
si
ty
 li
po
pr
ot
ei
n.
CI
, c
on
fid
en
ce
 in
te
rv
al
; e
GF
R,
 e
st
im
at
ed
 g
lo
m
er
ul
ar
 fi
ltr
at
io
n 
ra
te
.
Supplementary Table 4. Mean C-statistics for prediction of incident chronic kidney disease using 10-fold cross validation
Model C-statistics (95% CI)
P for difference of C-statistics compared with models
Model 1 Model 2 Model 3 Model 4
Model 1 0.643 (0.612-0.690) NA - - -
Model 2 0.728 (0.663-0.811) < 0.001 NA - -
Model 3 0.817 (0.765-0.854) < 0.001 < 0.001 NA -
Model 4 0.837 (0.797-0.867) < 0.001 < 0.001 < 0.001 NA
Model 1, sex, body mass index, education level, income, fasting glucose, and serum albumin; Model 2, model 1 + Framingham risk score; Model 3, model 1 + eGFR 
and proteinuria; Model 4, model 1 + eGFR, proteinuria, and the Framingham risk score. 
CI, confidence interval; eGFR, estimated glomerular filtration rate; NA, not applicable.
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Supplementary Figure 1. Receiver operating characteristics 
curve for 4 models predicting incident chronic kidney disease 
after 10-fold cross-validation. Model 1, sex, body mass index, 
education level, income, fasting glucose, and serum albumin; Model 
2, model 1 + Framingham risk score; Model 3, model 1 + eGFR + 
proteinuria; Model 4, model 1 + eGFR + proteinuria + Framingham 
risk score.
AUC, area under the curve; CI, confidence interval; eGFR, estimated 
glomerular filtration rate.
